TY - JOUR T1 - Protective drugs against Risk of Intra-coronary Stent ‎Restenosis ‎ A1 - Tarek Abdelmoneim Abdelaziz A1 - Randa Hussiny Mohammad A1 - Marwa Mohammed Gad A1 - Mohamed Gamel ‎Fawzy Ghareeb‎ JF - Journal of Advanced Pharmacy Education and Research JO - J Adv Pharm Educ Res SN - 2249-3379 Y1 - 2020 VL - 10 IS - 2 SP - 60 EP - 63 N2 - Background: Intracoronary stent restenosis (ISR) is a famous catastrophe, always following percutaneous coronary interventions (PCI). Many investigations were performed to avoid this complication by the addition of many cytotoxic drugs to stent platform for prevention of neo-intimal hyperplasia and smooth muscle cell proliferation, or by finding a protective drug against this problem, such as dual antiplatelet therapy. Our research was conducted to detect the protective drugs against the risk of intracoronary stent restenosis among all drugs of medical treatment for ischemic heart diseases. Results: The study reported that 54, 26, 54, and 34% of patients respectively administrated by clopidogrel, nitrates, angiotensin-converting enzyme inhibitors (ACEI) and statins developed ISR after PCI when compared to the other group of patients who did not develop ISR. So, these drugs were protective against the risk of ISR (P value0.05). Conclusions: This study concluded that clopidogrel, nitrates, ACEI, and statins are protective drugs against the risk of ISR complications after PCI procedures‎. UR - https://japer.in/article/protective-drugs-against-risk-of-intra-coronary-stent-restenosis ER -